Tivic Health Reports Significant 2025 Losses Amid Strategic Shift to Immunotherapy and Strong Cash Position
TIVC sits 26% above its 52-week low of $0.722 on light trading volume (0.2× avg).
Summary
Tivic Health Systems reported a substantial increase in net loss for 2025, reaching $8.8M-$9.1M, but also announced a strategic transformation into an immunotherapy company with a strong cash balance of $12.6M, driven by a recent convertible note.
Key Events · Earnings and Guidance · TIVC
-
Full Year 2025 Financial Results
The company reported an expected net loss for the year ended December 31, 2025, in the range of $8.8 million to $9.1 million, a significant increase from $5.7 million in 2024. Operating expenses also rose to $7.9 million from $4.5 million.
-
Strong Cash Position and Working Capital
Cash and equivalents at year-end 2025 totaled $12.6 million, a substantial increase from $2.0 million in 2024, providing a critical financial runway. Working capital stood at $12.4 million, supported by a $16.3 million Senior Secured Convertible Note Payable.
-
Strategic Transformation to Immunotherapy
Tivic Health completed its strategic transformation into a development-stage immunotherapy company, focusing on its Entolimod platform for acute radiation syndrome and oncology supportive care. The company also established Velocity Bioworks as a wholly-owned CDMO subsidiary.
-
Discussions for Government Funding
The company is engaged in discussions with U.S. government agencies, including BARDA, DTRA, NIH, and NIAID, regarding potential development funding and Strategic National Stockpile procurement for its Entolimod platform.
Analysis · TIVC · Industrial Applications And Services
Tivic Health Systems, a micro-cap company, reported a substantial increase in its net loss for the year ended December 31, 2025, reaching an expected range of $8.8 million to $9.1 million, up from $5.7 million in 2024. Operating expenses also rose significantly to $7.9 million. This comes shortly after a Nasdaq non-compliance notification on March 20, 2026. However, the company also announced a strategic transformation into a focused immunotherapy company, securing global rights to its Entolimod platform and establishing Velocity Bioworks as a CDMO subsidiary. Crucially, Tivic Health ended 2025 with a strong cash position of $12.6 million, up from $2.0 million, largely due to a $16.3 million Senior Secured Convertible Note Payable. This cash infusion provides a critical runway for its new strategic direction, including ongoing discussions with U.S. government agencies for potential Entolimod funding, which could be a significant non-dilutive capital source.
At the time of this filing, TIVC was trading at $0.91 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $0.72 to $13.23. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.